Journal
IMMUNOTHERAPY
Volume 10, Issue 9, Pages 797-805Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2017-0187
Keywords
checkpoint inhibitors; FDG-PET; immune-related response criteria; immune-PET; irRECIST; NSCLC
Categories
Funding
- Italian Association for Research on Cancer (Associazione Italiana per la Ricerca sul Cancro [AIRC])
- AIRC [18923]
Ask authors/readers for more resources
The treatment algorithm of advanced non-small-cell lung cancer is rapidly evolving. This result is mostly related to the availability in clinical practice of checkpoint inhibitors targeting the programmed death-1 (PD-1) and its ligands (PD-Ls) immunosuppressive pathway. Although patient's selection in the first-line setting relies essentially on high levels of PD-L1 tumor expression, treatment choice in pretreated patients is more challenging and, although clinical and biological characteristics might be of help, there is an urgent need for novel tools to better identify sensitive and resistant patients. In this context, the integration of molecular markers and immune-PET imaging might represent a potentially effective strategy to refine patient selection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available